Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Ulcer 1Tomaculous neuropathy 1Thrombocythemia, Essential 1Stomatitis 1Stomach Neoplasms 1Radiation Pneumonitis 1Primary Myelofibrosis 1Polycythemia Vera 1Polycystic Ovary Syndrome 1Neuroma 1Myeloproliferative Disorders 1Median Neuropathy 1Lung Neoplasms 1Lung Diseases, Interstitial 1Hand Injuries 1Disease 1Carpal Tunnel Syndrome 1Breast Neoplasms 1

Interventions

pembrolizumab 49Carboplatin 44Magnetic Resonance Spectroscopy 40Specimen Handling 39Pemetrexed 34Cisplatin 25Blood Specimen Collection 25durvalumab 17Paclitaxel 16osimertinib 15Radiotherapy 15Radiosurgery 15Bevacizumab 15Gemcitabine 14atezolizumab 13Nivolumab 13Biopsy 13Drug Therapy 12Standard of Care 10Practice Guidelines as Topic 10Immunoglobulin G 10Docetaxel 10130-nm albumin-bound paclitaxel 10X-Rays 9Taxes 9Educational Status 9Disulfides 9tislelizumab 8Etoposide 8Cetuximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lung Neoplasms × Acetylcysteine × Clear all
NCT05986318 2026-03-09

RESPIRE-ILD

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Recruiting
98 enrolled
Thoracic

Lung Neoplasms, Lung Diseases, Interstitial, Radiation Pneumonitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡